Fully Automated Closed Loop Control in Adolescents With Type 1 Diabetes

University of Virginia21 enrolled

Overview

The study team will be comparing two investigational Artificial Pancreas (AP) systems that the UVA Center for Diabetes Technology has developed. An artificial pancreas system delivers insulin automatically based on a blood glucose level that is provided from a continuous glucose monitor (CGM).

Maintaining blood glucose (BG) control among adolescents with Type 1 diabetes (T1D) is arguably the greatest challenge in the entire field of T1D. One reason for this poor control relates to missed meal boluses, which affects 65% of adolescents at least once weekly, with 38% missing at least 15% of their boluses. Adolescents who miss four boluses weekly experience an increase of 1% in their HbA1c. While the advent of the artificial pancreas (AP) offers promise of safe reductions in HbA1c, the study team previously found that the AP only partly compensates for missed prandial insulin -demonstrating that some form of meal announcement is necessary for good BG control, even with an AP. One way to automate this process is by sharing the prandial dosing responsibilities between an automated insulin priming (based on continuous glucose monitor condition predictive of a safe situation for such insulin dosing) and a closed loop controller capable of reconstructing (estimating) the prevailing glucose rate of appearance from an unannounced meal. The study team has developed such an insulin priming schema and integrated it into a new version of the robust Model Predictive Controller University of Virginia AP system (called the RocketAP). In the current study, the investigators are testing this new AP system in two configurations: hybrid and fully automated, among up to 20 adolescents. The primary outcome will be one of efficacy in assessing how well the new system controls post-prandial BG in the absence of carbohydrate (CHO) announcement as compared to the same situation but using the Control-IQ closed loop algorithm, also designed at UVa and using the same modular architecture and safety system, but without insulin priming and with a less advanced model-based controller. Further comparisons will be made to BG control on RocketAP with CHO announcement and on Control-IQ with CHO announcement. Adolescents will be started on the respective University of Virginia AP systems (RocketAP and Control-IQ in random order, both implemented on the DiAs platform, MAF 2109) and followed over the course of two dinners on each of the two platforms: a dinner where CHO is announced as normal and the 2nd where no announcement is made. The study team hypothesize that performances of RocketAP in fully automated mode will lie in between Hybrid and Fully Automated Control-IQ. In time, this may provide an opportunity to improve BG control among adolescents who miss meal announcement.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Type 1 Diabetes

Interventions

RocketAPDEVICE

Artificial pancreas system which is designed to be able to identify when you have eaten and provide insulin for this meal

USS VirginiaDEVICE

Artificial pancreas system which responds to glucose fluctuations by modulating insulin delivery but does not specifically detect meal ingestion

Eligibility

Sex: ALLMin age: 12 YearsMax age: 25 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥12.0 and ≤25 years old at time of consent 2. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year 3. Currently using insulin for at least six months 4. Currently using insulin pump for at least three months 5. Using insulin parameters such as carbohydrate ratio and correction factors consistently on their pump in order to dose insulin for meals or corrections 6. Access to internet and willingness to upload data during the study as needed 7. For females, not currently known to be pregnant or breastfeeding 8. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued. 9. Willingness to suspend use of any personal CGM for the duration of the clinical trial once the study CGM is in use 10. Willingness to use the UVa artificial pancreas system throughout study sessions. 11. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the study 12. Total daily insulin dose (TDD) at least 10 U/day and not more than 100 U/d 13. Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial (including metformin, GLP-1 agonists, pramlintide, DPP-4 inhibitors, biguanides, sulfonylureas and naturaceuticals) 14. Willingness to eat at least 1 g/kg of carbohydrate per day during the camp/hotel admission 15. Willingness to reschedule Study Dinner Sessions if placed on oral steroids 16. An understanding and willingness to follow the protocol and signed informed consent Exclusion Criteria: 1. History of diabetic ketoacidosis (DKA) in the 12 months prior to enrollment 2. Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment 3. Pregnancy or intent to become pregnant during the trial 4. Currently being treated for a seizure disorder 5. Planned surgery during study duration 6. Treatment with any non-insulin glucose-lowering agent (including metformin, GLP-1 agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals) 7. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol. 8. Use of an automated insulin delivery mechanism that is not downloadable by the subject or study team

Locations (1)

University of Virginia Center for Diabetes Technology

Charlottesville, Virginia, United States

Outcomes

Primary Outcomes

Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range 70-180 mg/dL in the Unannounced Meal

Percentage of time from dinner time until midnight with blood glucose in range 70-180 mg/dL in the unannounced meal

Time frame: 6 hours

Secondary Outcomes

Number of Hypoglycemia Events From Dinner Time Until Midnight

Number of hypoglycemia events from dinner time until midnight

Time frame: 6 hours

Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range < 70 mg/dL

Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range \< 70 mg/dL

Time frame: 6 hours

Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range >180 mg/dL

Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range \>180 mg/dL

Time frame: 6 hours

Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range >250 mg/dL

Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range \>250 mg/dL

Time frame: 6 hours

Units of Insulin Injected From Dinner Time Until Midnight

Units of insulin injected from dinner time until midnight

Time frame: 6 hours

The Blood Glucose Area Under the Curve (AUC) From Dinner Until Midnight, Accounting for the Initial Blood Glucose Value

The blood glucose area under the curve (AUC) from dinner until midnight, accounting for the initial blood glucose value.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.